// App-Quantinova.ai

: ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

Researchers

Presenter

  • Nancy Levin

Principal Investigators

  • Benjamin Winograd

  • Warren Mason

Medical Centers

  • Triphase Accelerator, La Jolla,, CA

  • University of California, Irvine, Orange, CA, USACelgene, Summit, NJ, USA

  • University of Toronto, University Health Network, Toronto, Ontario, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Temozolomide

  • Marizomib

Outcome

  • N/A

Study Design

  • Open Label

  • Multinational

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT03345095

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved